Contrasting of Sierra Oncology Inc. (SRRA) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)

Sierra Oncology Inc. (NASDAQ:SRRA) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sierra Oncology Inc. N/A 0.00 54.84M -0.76 0.00
Arrowhead Pharmaceuticals Inc. 94.79M 25.83 9.57M 0.07 262.60

Demonstrates Sierra Oncology Inc. and Arrowhead Pharmaceuticals Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 represents Sierra Oncology Inc. (NASDAQ:SRRA) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Sierra Oncology Inc. 0.00% -43.8% -40.2%
Arrowhead Pharmaceuticals Inc. 10.10% 6.7% 4.3%

Volatility & Risk

Sierra Oncology Inc. has a beta of 1.67 and its 67.00% more volatile than S&P 500. Arrowhead Pharmaceuticals Inc.’s 106.00% more volatile than S&P 500 volatility due to the company’s 2.06 beta.


10.8 and 10.8 are the respective Current Ratio and a Quick Ratio of Sierra Oncology Inc. Its rival Arrowhead Pharmaceuticals Inc.’s Current and Quick Ratios are 2.3 and 2.3 respectively. Sierra Oncology Inc. has a better chance of clearing its pay short and long-term debts than Arrowhead Pharmaceuticals Inc.

Analyst Ratings

Sierra Oncology Inc. and Arrowhead Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sierra Oncology Inc. 0 0 0 0.00
Arrowhead Pharmaceuticals Inc. 0 0 1 3.00

Meanwhile, Arrowhead Pharmaceuticals Inc.’s consensus price target is $165, while its potential upside is 539.04%.

Insider and Institutional Ownership

Sierra Oncology Inc. and Arrowhead Pharmaceuticals Inc. has shares held by institutional investors as follows: 66.7% and 63.9%. Insiders held roughly 0.1% of Sierra Oncology Inc.’s shares. Comparatively, Arrowhead Pharmaceuticals Inc. has 4.2% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sierra Oncology Inc. 6.25% 9.29% -0.65% -7.83% -35.44% 15.91%
Arrowhead Pharmaceuticals Inc. 4.58% 2.79% 10.94% 32.3% 103.5% 54.35%

For the past year Sierra Oncology Inc. has weaker performance than Arrowhead Pharmaceuticals Inc.


Arrowhead Pharmaceuticals Inc. beats Sierra Oncology Inc. on 10 of the 11 factors.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.